Flexible bronchoscopy is an important tool in the diagnosis of pulmonary complications following bone marrow transplantation. However, the value of this procedure in autologous peripheral stem cell transplant (APSCT) recipients with pulmonary complications is not well defined. We retrospectively evaluated the diagnostic yield of 27 consecutive bronchoscopies done on 23 APSCT recipients following high-dose chemotherapy for breast cancer. FB resulted in a positive diagnosis in 16 cases (59%). Broncheoalveolar lavage (BAL) was performed on all patients, and transbronchial biopsies (TBB) were carried out in 14. TBB were diagnostic in 10 (71%), with pulmonary drug toxicity as the most common finding (n ‫؍‬ 8), followed by metastatic breast cancer (n ‫؍‬ 2). BAL was diagnostic in six (22%): bacterial pneumonia (n ‫؍‬ 3), aspergillosis (n ‫؍‬ 2), Pneumocystis carinii pneumonia (n ‫؍‬ 1) and Influenza B (n ‫؍‬ 1). The procedure was well tolerated with no major complications except a small pneumothorax in one patient that did not require chest tube insertion. In conclusion, flexible bronchoscopy is a useful tool in the evaluation of pulmonary complications following APSCT for breast cancer. TBB can be done safely with relatively high diagnostic yield. Pulmonary drug toxicity is the most common pathological finding. Bone Marrow Transplantation ( nant and nonmalignant disorders. Pulmonary complications are estimated to be in the range of 40-60%, and are a major cause of morbidity and mortality in these patients.
nant and nonmalignant disorders. Pulmonary complications are estimated to be in the range of 40-60%, and are a major cause of morbidity and mortality in these patients. [1] [2] [3] Recently, there has been a growing interest in the use of high-dose chemotherapy (HDC) followed by autologous peripheral stem cell transplantation (APSCT) for the treatment of a variety of conditions, especially advanced breast cancer, lymphoma and brain tumors as well as nonmalignant conditions like scleroderma. [4] [5] [6] Pulmonary complications are generally less frequent and less severe following APSCT when compared to allogeneic BMT, mainly due to less immunosuppression and absence of graft-versus-host disease. However, recent reports indicate that pulmonary drug toxicity is a major complication of APSCT, and this is primarily related to the use of carmustine (BCNU), which is central to different HDC regimens. 7 Pulmonary drug toxicity is commonly diagnosed and treated based on clinical grounds. However, there are situations where the clinical picture is not clear, and there is suspicion of infection or cancer recurrence, or the patient does not respond well to corticosteroids. In these situations further invasive procedures, including flexible bronchoscopy (FB) are usually necessary. Although the role of FB in the evaluation of pulmonary infiltrates following BMT in general, has been studied extensively, 8, 9 its role in patients with pulmonary complications following HDC and APSCT is not well studied. Accordingly, we retrospectively studied the bronchoscopic findings in all patients who underwent FB for evaluation of pulmonary problems following HDC and APSCT for the treatment of advanced breast cancer.
Methods
At Karmanos Cancer Institute there is an active stem cell transplantation program. Over a 2 year period, 224 patients underwent HDC followed by APSCT for the treatment of advanced breast cancer. All patients received HDC with BCNU, cyclophosphamide and cisplatinum followed by APSCT. The protocol used at our institution has been previously described. 10 Patients who presented with dyspnea, dry cough and reduction in diffusion capacity (DLCO)
Bone Marrow Transplantation (corrected DLCO Ͻ70% of predicted or 20% reduction from baseline), with or without pulmonary infiltrates were presumed to have pulmonary drug toxicity, and were treated with corticosteroids (prednisone 60 mg/day tapered over 10 weeks). If the patients had high fever, chest pain, sputum production or lobar infiltrate, they were started on broad-spectrum antibiotics for suspected bacterial pneumonia. The decision to perform FB was made on an individual basis by the treating physicians, and the main indications were lack of response to the above treatment, or radiological features suspicious of opportunistic pulmonary infection or recurrence of breast cancer (eg nodular of multifocal infiltrate). During this period there were 27 FBs performed as part of the diagnostic work up. The procedure was carried out according to conventional technique. All patients underwent bronchoalveolar lavage (BAL), and 14 had transbronchial biopsies (TBB) from the segments involved radiologically. Platelet transfusions were given prior to the procedure in five patients to increase the platelet count above 50 000/mm 3 . Chest radiographs were obtained within 24 h of the procedure.
The medical records of the patients were retrospectively reviewed in detail, including demographic data, presenting symptoms, radiologic findings, indications and timing of FOB following APSCT, whether they were on mechanical ventilation or not, and findings of FB and complications of the procedure. Information was also obtained on patient outcome and autopsy findings if performed. The bronchoscopic diagnosis was made based on microbiological, cytological and histopathological proof of disease, with comparable clinical and radiological pictures. The diagnosis of pulmonary drug toxicity was made when the clinical, radiological and DLCO findings were consistent with the diagnosis, and the biopsy specimen showed mononuclear inflammatory interstitial infiltrate, interstitial fibrosis or reactive hyperplastic type II pneumocytes, with negative stains and cultures for infectious process.
11 Metastatic breast cancer was diagnosed when malignant cells consistent with primary breast cancer were detected histopathologically on the TBB. Bacterial pneumonia was diagnosed when bacteria were isolated by culture in a patient with respiratory symptoms and radiological findings consistent with the diagnosis, and the patient improved with appropriate antibiotic therapy. Aspergillus lung infection was diagnosed when the characteristic hyphae were detected in the lavage by stain or culture with the appropriate clinical picture or on histopathological examination of a lung specimen. Pneumocystis carinii pneumonia was diagnosed when the cysts were detected by methamine silver stain. Influenza B pneumonia was diagnosed when the virus was detected by direct fluorescence stain and compatible clinical and radiological pictures.
Results
There were 27 FB carried out on 23 APSCT recipients following HDC for the treatment of advanced breast cancer. Table 1 summarizes the baseline characteristics of these patients. All patients underwent BAL, and 14 (52%) had TBB. Eighty-five percent of the patients were hospitalized at the time of the procedure. The median time of FB following transplantation was 12 weeks; only four cases were in the first 4 weeks following transplantation, and 14 were carried out after 12 weeks. The diagnostic yield of the FB is summarized in Table 2 . Overall, bronchoscopy yielded a positive finding in 16 cases (59%). BAL was diagnostic in six cases (22%); all were infectious (gram-positive bacteria in three, Aspergillus in one, both Aspergillus and Pneumocystis carinii in one, and influenza B in one). The median time from transplant for those patients was 11 weeks (range 4-78 weeks). TBB was diagnostic in 10 of 14 patients in whom the procedure was carried out (71%).
In eight cases the findings were consistent with pulmonary drug toxicity (the median corrected DLCO was 40% (range 32-64%). In two cases metastatic breast cancer was diagnosed. No infectious etiology was diagnosed by this intervention. TBB contributed to a positive diagnosis in 37% of all patients who underwent FB. The median time from transplant for patients diagnosed with noninfectious pulmonary problems was 14 weeks (range 7-40 weeks). Open lung biopsy was performed in two cases (1 and 1. weeks following a nondiagnostic FB, and revealed herpes simplex pneumonitis and Aspergillus infection, respectively). No correlation could be detected between positive bronchoscopic findings and the radiological pattern, timing of Table 2 Results of flexible bronchoscopy in APSCT ) or deaths related to the procedure.
Seven patients died during the study period, and six underwent autopsy 1 to 2. weeks following the FB. Three had diffuse pulmonary fibrosis, two diffuse alveolar damage and one diffuse alveolar hemorrhage. Additional autopsy findings were metastatic breast cancer in two, acute pulmonary embolism in two, and subacute pulmonary infarction with no evidence of fungal infection in another two patients. Three of those patients underwent TBB and the findings were consistent with pulmonary drug toxicity, while FB in the remainder were nondiagnostic.
Discussion
This study evaluated the results of FB in APSCT recipients following HDC for the treatment of advanced breast cancer. It showed that this procedure had a relatively high diagnostic value (59%), and in selected patients TBB could be done relatively safely with high yield. Pulmonary drug toxicity and metastatic breast cancer were the most common findings. Infectious complications were much less frequently diagnosed by FB (22%). All the diagnoses were made by BAL and were mainly bacterial or fungal. No correlations could be detected between positive bronchoscopic findings and the radiologic pattern, timing of the procedure following transplantation or mechanical ventilation. This may be related to the small sample size. The value of bronchoscopy in the evaluation of pulmonary disease following BMT has been studied extensively, with variable results, mainly due to an heterogeneous patient population (Table 3) . BAL is the most commonly used bronchoscopic procedure and has a yield that ranges between 31 and 89%, with the main findings being infectious process or diffuse alveolar hemorrhage. 8, 9, [12] [13] [14] [15] [16] [17] [18] [19] There were two other studies 16, 19 that reported a diagnostic yield around 40% for FB in autologous BMT recipients; however, these were based on BAL alone -without TBB -which is less sensitive in the diagnosis of noninfectious pulmonary complications such as pulmonary drug toxicity. TBB is less commonly carried out in BMT recipients due to concerns about complications, especially bleeding, in this fragile patient population. In one study, the reported yield of TBB in a cohort of BMT recipients was 58%. 20 The diagnostic yield of TBB in the diagnosis of pulmonary drug toxicity or metastatic tumor in immunocompromised patients has been reported to be in the range of 40-65%. [21] [22] [23] Our study compares favorably with other studies, and is the only study to our knowledge that looks at a homogenous group of APSCT recipients following HDC. Of interest is that TBB had a relatively high diagnostic yield, and could be done relatively safely in selected patients following APSCT. This is probably related to the fact that these patients are generally less thrombocytopenic and the procedure is rarely needed in the first few weeks following transplantation, when they are most at risk. As expected in this patient population, histological features consistent with drug toxicity were the main finding of TBB, followed by metastatic breast cancer. TBB did not contribute to the diagnosis of infectious process in our patients. A similar observation was reported by others. 20 In our study, there were fewer positive results with BAL, and all were infectious processes. This is believed to be due to better engraftment in APSCT recipients, less immunosuppressive therapy, no GVHD and more standard use of prophylactic antimicrobial therapy in patients receiving high-dose corticosteroids for the treatment of pulmonary drug toxicity.
Pulmonary drug toxicity is an important problem following HDC and APSCT for the treatment of breast cancer, and has been reported in 31-72% of patients. 5, 24, 25 The majority of evidence suggests that the toxicity is related to high-dose BCNU used in the conditioning regimen; however, some studies suggest that there is synergism between BCNU and cyclophosphamide leading to the higher incidence of pulmonary drug toxicity observed in this patient population. 11 The pulmonary toxicity due to BCNU is believed to be mediated by DNA damage and oxidant mechanisms. 7, 26 In a study of 10 patients who developed pulmonary drug toxicity following HDC and APSCT for breast cancer and underwent pathologic examination of the lung (open lung biopsy in five, TBB in four, both open lung biopsy and TBB in one, and three of those had autopsy examination), there were five major pathological findings: alveolar septal thickening with fibrosis, atypical type II pneumocytes, vascular injury, intra-alveolar edema, and increased intra-alveolar macrophages. 11 The first two findings were described in all patients, while pulmonary vascular injury and intra-alveolar edema and macrophages were not detected in patients who underwent TBB, generally due to the smaller samples obtained by this procedure.
Recently, the syndrome of pulmonary drug toxicity associated with HDC and APSCT has been better characterized and termed delayed pulmonary toxicity syndrome (DPTS) 25 to reflect its higher incidence, lower mortality and apparent better responsiveness to corticosteroid therapy when compared to idiopathic pneumonitis syndrome which is primarily seen in allogeneic BMT recipients and has a far worse prognosis. 27 DPTS usually presents 2-16 weeks following HDC/APSCT with dyspnea and nonproductive cough that are often associated with fever. The radiological findings are nonspecific and could range from normal to ground glass appearance, linear or even nodular opacities. Pulmonary function testing characteristically shows reduction in diffusion capacity. Treatment with corticosteroids usually shows dramatic rapid resolution of symptoms; however, this response is not uniform, and at least one-third of patients relapse following withdrawal of therapy and require prolonged treatment. Some patients die from progressive respiratory failure. 24 Although the diagnosis of pulmonary drug toxicity is usually made on clinical grounds, supported by the results of pulmonary function tests, 28 some patients have atypical presentation, do not respond to corticosteroids, or there is suspicion that the pulmonary findings are due to an infectious process or relapse of the underlying malignancy. It is in these situations that further evaluation is usually necessary, and our study shows that FB is useful in the evaluation of this selected group of patients.
Of the seven patients who died during the study period, six underwent post-mortem examination. Four had evidence of acute or subacute pulmonary thromboembolism. However, in each case this finding was associated with histological features of pulmonary drug toxicity and/or metastatic breast cancer. Thus it should be kept in mind that these patients are at risk for other conditions not directly related to the transplant, but to the fact that they are acutely ill, immobilized and have underlying malignancy. Appropriate prophylaxis against these conditions is warranted.
In conclusion, FB is a useful tool in the evaluation of pulmonary infiltrates following HDC and APSCT for the treatment of advanced breast cancer. In selected patients, TBB can be carried out safely with a relatively high diagnostic yield. Features consistent with pulmonary drug toxicity were the most common finding, while infectious complications were less frequently diagnosed in this patient population.
